Oculis (NASDAQ:OCS) Sets New 52-Week Low – Time to Sell?

Oculis Holding AG (NASDAQ:OCS) reached a new 52-week low on Thursday . The company traded as low as $9.65 and last traded at $9.3460, with a volume of 6271 shares. The stock had previously closed at $9.99.

Analyst Upgrades and Downgrades

OCS has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research note on Friday, July 17th. Robert W. Baird reduced their price objective on Oculis from $49.00 to $38.00 and set an “outperform” rating on the stock in a research report on Monday, June 1st. Needham & Company LLC lowered their target price on Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a report on Monday, June 1st. Guggenheim dropped their target price on Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Finally, HC Wainwright lifted their price target on Oculis from $26.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, September 18th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $39.44.

Oculis Trading Down 5.7%

The company has a market cap of $546.46 million, a price-to-earnings ratio of -5.45 and a beta of 0.52. The business’s fifty day moving average price is $11.86 and its 200 day moving average price is $18.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.35 and a quick ratio of 8.35.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. The company had revenue of $0.38 million during the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. Research analysts anticipate that Oculis Holding AG will post -2.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oculis

Several institutional investors and hedge funds have recently made changes to their positions in OCS. Squarepoint Ops LLC raised its stake in Oculis by 326.4% during the second quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock worth $854,000 after buying an additional 47,158 shares during the last quarter. Braidwell LP bought a new stake in Oculis during the second quarter valued at $11,570,000. Bank of America Corp DE boosted its position in Oculis by 9.1% during the first quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock valued at $1,855,000 after acquiring an additional 5,813 shares during the last quarter. Himension Capital Singapore PTE. LTD. acquired a new stake in Oculis during the 1st quarter worth about $503,000. Finally, Koshinski Asset Management Inc. acquired a new stake in Oculis during the 1st quarter worth about $238,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Company Profile

Oculis is a clinical-stage biopharmaceutical company focused on developing ophthalmic therapies for eye diseases and vision loss. The company uses proprietary drug-delivery technologies designed to improve the delivery of treatments to specific tissues in the eye, with the goal of offering effective and convenient alternatives to injections or other invasive procedures.

Oculis’ pipeline includes OCS-01, a topical eye-drop formulation of dexamethasone being developed for diabetic macular edema and inflammation following ocular surgery.